Cencora agreed to partner with Kite to distribute Kite’s FDA-approved CAR T-cell therapies Yescarta and Tecartus across the U.S. The collaboration is aimed at expanding patient access at authorized treatment centers, including health systems and community oncology practices. The deal centers on Cencora’s specialty distribution infrastructure to reduce administrative burdens for providers as Kite expands its center network. For cell therapies, distribution and logistics can be just as operationally demanding as clinical administration, and expanding beyond academic hospitals remains a key growth lever. For commercialization teams and operations leaders, the transaction reflects continued maturation of CAR T access models—shifting from trial-era center concentration to broader care delivery networks supported by specialized third-party logistics.